Alteration of STAT3 gene expression in psoriasis treatment

Introduction. Psoriasis is a typical complex multigenic and multifactorial disease with heterogeneous genetic heredity, which requires the interaction of genes both with each other and with environmental factors. STAT3 (Signal Transducer and Activator of Transcription 3) has only recently been considered a key player in the development and pathogenesis of psoriasis and psoriatic inflammatory conditions.

Aim of the study. To study the expression of the STAT3 gene in the affected part of the skin of psoriasis patients in relation to the visually unaffected part. To study the change in the STAT3 gene expression level in psoriasis-affected skin as compared to nonaffected skin in patients before and after treatment with low-level laser radiation at a wavelength of 1.27 pm.
Materials and methods. The study involved 12 psoriasis patients. Biopsies from the unaffected skin were taken at a distance of about 3 cm from the affected skin. Real-time PCR analysis was performed.
Results and discussion. The expression of the STAT3 gene was quantitatively measured using RT-PCR in the affected part of the skin of psoriasis patients compared to the visually unaffected part of the skin of the same patients before and after treatment with low-level laser radiation with a wavelength of 1.27 gm (short-wave infrared). As a result of the study, an increase in the expression of the STAT3 gene in the affected part of the skin of psoriasis patients of an average of 3.96 ± 2 times was experimentally shown. A decrease in gene expression was observed in psoriasis affected skin compared to samples of non-affected areas. After treatment of patients with low-level laser radiation, a significant reduction in the expression of the overexpressed STAT3 gene to 1.75 ± 0.5 times was observed.
Conclusions. The transcription activity of the STAT3 gene can be an indicator of the efficacy of psoriasis treatment at the molecular level and can also be a new therapeutic target.

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314-320. doi: 10.1046/j.1365-2230.2001.00832.x.

2. Boehncke W.H., Schon M.P. Psoriasis. Lancet. 2015;386(9997):983-994. doi: 10.1016/S0140-6736(14)61909-7.

3. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350. doi: 10.1038/jid.2009.59.

4. Samuelsson L., Enlund F., Torinsson A., Yhr M., Inerot A., Enerback C. et al. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum Genet. 1999;105(6):523-529. doi: 10.1007/s004399900182.

5. Merve H.M., Sevilay K., Sibel O., Basac B., Ceren C.G., Demirci T., Cuneyt A. Psoriasis and Genetics. In: Chiriac A. (ed.) An Interdisciplinary Approach to Psoriasis. 2017. doi: 10.5772/intechopen.68344.

6. Barker J.N. Genetic aspects of psoriasis. Clin Exp Dermatol. 2001;26(4):321-325. doi: 10.1046/j.1365-2230.2001.00830.x.

7. Sobolev V.V., Zolotarenko A.D., Soboleva A.G., Sautin M.E., Il'ina S.A., Sarkisova M.K. et al. Expression of the FOSL1 gene in psoriasis and atherosclerosis. Genetika = Russian Journal of Genetics. 2010;46(1):104-110. (In Russ.) Available at: http://www.vigg.ru/genetika.

8. Sobolev V.V., Zolotorenko A.D., Soboleva A.G., Elkin A.M., Il'ina S.A., Serov D.N. et al. Effects of Expression of Transcriptional Factor AP-1 FOSL1 Gene on Psoriatic Process. Bull Exp Biol Med. 2011;150(5):632-634. doi: 10.1007/s10517-011-1208-0.

9. Sobolev V.V., Nikol'skaya T.A., Zolotarenko A.D., Piruzyan E.S., Bruskin S.A. Expression of bioinformatically identified genes in skin of psoriasis patients. Russ J Genet. 2013;49(10):1057-1064. doi: 10.1134/S1022795413100116.

10. Calautti E., Avalle L., Poli V. Psoriasis: A STAT3-Centric View. Int J Mol Sci. 2018;19(1):171. doi: 10.3390/ijms19010171.

11. Sestito R., Madonna S., Scarponi C., Cianfarani F., Failla C.M., Cavani A. et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J. 2011;25(3):916-927. doi: 10.1096/fj.10-172288.

12. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., Dong C. STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells. J Biol Chem. 2007;282(13):9358-9363. doi: 10.1074/jbc.C600321200 .

13. Harris T.J., Grosso J.F., Yen H.-R., Xin H., Kortylewski M., Albesiano E. et al. Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity. J Immunol. 2007;179(7):4313-4H317. doi: 10.4049/jimmunol.179.7.4313.

14. Livak K.J., Schmittgen T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-AAC(T)) Method. Methods. 2001;25(4):402-408. doi: 10.1006/meth.2001.1262.

15. Yao Y., Richman L., Morehouse C., de los Reyes M., Higgs B.W., Boutrin A. et al. Type I Interferon: Potential Therapeutic Target for Psoriasis? PLoS One. 2008;3(7):e2737. doi: 10.1371/journal.pone.0002737.

16. Chowdhari S., Saini N. hsa-miR-4516 Mediated Downregulation of STAT3/ CDK6/UBE2N Plays a Role in PUVA Induced Apoptosis in Keratinocytes. J Cell Physiol. 2014;229(11):1630-1638. doi: 10.1002/jcp.24608.

17. Grabarek B., Wcislo-Dziadecka D., Gola J., Kruszniewska-Rajs C., Brzezinska-Wcislo L., Zmarzly N., Mazurek U. Changes in the Expression Profile of JAK/ STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab Therapy. Curr Pharm Biotechnol. 2018;19(7):556-565. doi: 10.2174/1389201019666180730094046.

18. Grabarek B., Krzaczynski J., Strzalka-Mrozik B., Wcislo-Dziadecka D., Gola J. The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control. Dermatol Ther. 2019;32(5):e13029. doi: 10.1111/dth.13029.

19. Bovenschen H.J., van de Kerkhof P.C., van Erp P.E., Woestenenk R., Joosten I., Koenen H.J. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. J Invest Dermatol. 2011;131(9):1853-1860. doi: 10.1038/jid.2011.139.

20. Shu Y., Hu Q., Long H., Chang C., Lu Q., Xiao R. Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases. Clin Rev Allergy Immunol. 2017;52(2):260-272. doi:10.1007/s12016-016-8590-10.1007/s12016-016-8590-3.